Fig. 2From: Payload diversification: a key step in the development of antibody–drug conjugatesStructure of topoisomerase I inhibitors-based ADCs. A FDA-approved ADCs and payloads (purple) and ADCs and payloads under clinical evaluation (blue). B Topoisomerase 1 inhibitors used in preclinical development (green). C Next-generation topoisomerase I inhibitors as potential payloads for ADCs. Notations within the figure: [ADC name], antibody, payloadBack to article page